Cediranib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Cediranib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.[1][2][3]
Quick Facts Clinical data, Routes ofadministration ...
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 12 to 35 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.196.628 |
Chemical and physical data | |
Formula | C25H27FN4O3 |
Molar mass | 450.514 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.